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Abstract
Despite the availability of powerful antibiotics, community-acquired pneumonia (CAP) remains one
of the leading reasons for morbidity and mortality worldwide, and despite the availability of powerful
antibiotics, there has been only little improvement in case fatality rates for many years. Consequently,
it cannot be expected that novel antibiotics will substantially improve outcomes in CAP. Therefore,
this review focuses on novel approaches that may reduce CAP-related mortality: the impact of
immunomodulation by macrolides and fluoroquinolones and the prevention of CAP by
pneumococcal vaccines.
Introduction and context
Despite the availability of powerful antibiotics, com-
munity-acquired pneumonia (CAP) remains one of the
leading reasons for morbidity and mortality world-
wide. Case fatality rates vary widely among patients
with CAP. Recent data of the German CAPNETZ
(competence network for community-acquired pneu-
monia) show that fatality rates were 0.5% for out-
patients and 14% for hospitalized patients [1]. Owing
to insufficient diagnostic tools, pathogens are detected
in only 30-50% of hospitalized patients with CAP. In
most studies, Streptococcus pneumoniae is by far the
leading pathogen in CAP. A study using transthoracic
needle aspiration showed that S. pneumoniae is found
frequently when sputum and blood culture fail to
detect any pathogen [2].
During the last decade, the case fatality rate of patients
hospitalized with CAP has not really changed. There-
fore, novel approaches are needed to further improve
outcome in hospitalized patients with CAP. Recent
advances in CAP include the recognition of anti-
inflammatory strategies and prevention of CAP by
vaccination.
Recent advances
Treatment
The primary rationale for the use of antibiotics in the
treatment of CAP is undoubtedly their direct anti-
microbial effect. But in the last two decades, growing
evidence has shown that at least some classes of
antibiotics possess beneficial properties that go beyond
just killing of the causative agent; they appear to
modulate the host’s immune response. The best known
and investigated are the immunomodulatory effects of
macrolides and to a certain degree the immuno-
relevant actions of quinolones.
Immunomodulatory properties of antibiotics were
recognized firstly in macrolides more than 20 years
ago, when the 5-year survival rate of patients with diffuse
panbronchiolitis (DPB) could be improved from less
than 50% (approximately 8% if the patient was
chronically colonized with Pseudomonas aeruginosa)t o
approximately 90% by long-term administration of
erythromycin, despite macrolide resistance of the
involved pseudomonal strains and application in sub-
antimicrobial doses [3,4]. Subsequently, great efforts
have been taken to elucidate the underlying mechanisms
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ference of antibiotic agents with neutrophil activation
and mobilization, neutrophil apoptosis, activation of
nuclear transcription factors, production of reactive
oxygen species, airway mucus secretion, and bacterial
bio-film [5]. Specifically, macrolides possess the ability
to suppress the production and secretion of pro-
inflammatory cytokines from monocytes and normal
human bronchial epithelial cells through the inhibition
of extracellular signal-regulated kinases (ERKs). Owing
in part to direct and indirect downregulation of nuclear
factor-kappa-B (NF-kB), this leads to decreased levels of
interleukin (IL)-8, tumor necrosis factor-alpha (TNF-a),
granulocyte-macrophage colony-stimulating factor, and
IL-1b [6,7]. As a consequence of lower levels of IL-8 and
other chemo-attractants and adhesion molecules (e.g.,
E-selectin and intercellular adhesion molecule-1),
macrolides inhibit the recruitment and accumulation
of neutrophil granulocytes at the site of inflammation
and thus prevent the release of lysosomal enzymes and
generation of reactive oxygen species and the resulting
airway damage. This effect was confirmed recently by
Bosnar et al. [8], who demonstrated that pre-treatment
with azithromycin and clarithromycin prior to lipoploy-
saccharide (LPS) challenge in mice can significantly
reduce total cell and neutrophil numbers in bronchoal-
veolar lavage fluid (BALF) and myeloperoxidase con-
centration in lung tissue.
Respiratory quinolones have also been shown to impair
macrophage chemotaxis in rats and to significantly reduce
transendothelial neutrophil and monocyte migration
[9,10]. In addition, Weiss et al. [11] demonstrated that
pre-incubation of LPS-activated human monocytes
with moxifloxacin causes a concentration-dependent
inhibition of the synthesis of IL-1b, IL-8, and TNF-a.P r e -
incubation with moxifloxacin was also associated with
reduced expressions of NF-kB, ERK, and c-Jun N-terminal
kinase [11]. Recently, Ogino et al. [12] confirmed the
inhibitory effect of different fluoroquinolones on LPS-
induced pro-inflammatory cytokine production (IL-1b
and TNF-a)i nm u r i n ein vivo and in vitro experiments. In
addition, they found that this effect can be attributed in
particular to those fluoroquinolones with a cyclopropyl
groupattheN1position(e.g.,ciprofloxacin,moxifloxacin,
grepafloxacin, and sparfloxacin).
Whereas the beneficial effects of macrolides in chronic
pulmonary inflammatory conditions like DPB, cystic
fibrosis, or bronchiolitis obliterans syndrome after lung
transplantation are widely accepted [13], their impact on
acute pulmonary inflammation is currently under
intensive investigation. Experimental studies investigat-
ing the immunomodulatory actions of macrolides and
ketolides in murine models of acute pneumonia caused
by Mycoplasma pneumonia and Chlamydia pneumophilia
showed decreased concentrations of various pro-inflam-
matory cytokines (e.g., IL-1b, IL-8, and TNF-a) in BALF
and reduced lung histological signs of inflammation,
although complete bacterial eradication could not be
achieved in all cases [14-16]. Therefore, it might be
concluded that macrolides provide immunomodulatory
effects in acute inflammation.
The first clinical evidence for the probability of immuno-
modulatory effects of macrolides, even in acute inflam-
mation, was derived mainly from retrospective cohort
studies evaluating the impact of an additional macrolide
treatment in patients with CAP [17-19]. These studies
could demonstrate that the addition of a macrolide to a
beta-lactam significantly decreased the risk of death. This
effect was also seen in severely ill patients with severe
sepsis due to pneumonia [20]. Tessmer et al. [21] recently
evaluated the benefit of beta-lactam/macrolide combina-
tion therapy (BLM) versus beta-lactam monotherapy in a
prospective cohort study that included hospitalized
patients with CAP. The authors could clearly demonstrate
a significantly reduced adjusted mortality rate in patients
with severe CAP (confusion, respiratory rate, blood
pressure, and age [whether below or above 65 years old]
score [CRB65] of at least 2) receiving BLM therapy.
Interestingly, this effect was not seen in mild to moderate
pneumonia (CRB65 of not more than 1). Finch et al. [22]
demonstrated a similar clinical effect for quinolones.
In conclusion, there is strong evidence of an immuno-
modulatory effect of macrolides and some evidence of
an immunomodulatory effect of quinolones in acute
pulmonary inflammation and a subsequent clinical
benefit in terms of improved outcome and survival in
CAP. Unfortunately, most data derive from retrospective
or non-randomized prospective trials. Hence, before the
potential advantage of macrolides and quinolones in the
treatment of CAP can be generally stated, prospective
randomized controlled studies are required.
Statins are considered to have anti-inflammatory effects
and prior use of statins has been linked to improved
outcome of CAP. In a monocenter prospective observa-
tional study, Chalmers and colleagues [23] found that
patients on statins had a higher severity of disease
according to the pneumonia severity index but a
decreased 30-day mortality (adjusted odds ratio 0.46).
As a marker of inflammation, C-reactive protein was
lower and decreased earlier in these patients. The authors
controlled for the so-called ‘healthy-user effect’ by
demonstrating that other drugs prescribed for cardiovas-
cular disease had no influence on the outcome of CAP.
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of prior statin use on the risk of CAP in a population-
based cohort of older individuals (more than 65 years)
[24]. In this case control study, inhabitants of nursing
homes were excluded because they are more likely to
suffer from certain severe comorbid illnesses, frailty, and
cognitive or functional impairment and thus are at
increased risk of pneumonia. Despite the increased risk
of CAP, frail older people or those with more severe
comorbidities are less likely to receive statins [25]. In
addition, subjects receiving statins tend to practice other
healthy behaviors, like physical activity or smoking
cessation, and are more likely to have better functional
status and comorbidity that is less severe. Hence, the
authors postulate that a ‘healthy-user bias’ is responsible
for the decreased CAP risk that has been described in
earlier studies.
Since the two studies had differentendpoints (outcomeof
CAP[23]versusriskofCAP[24]),itisdifficulttodrawany
final conclusion from their findings. Therefore, the results
of prospective randomized controlled trials that address
the immunomodulatory properties of statins and that are
currently under way should be awaited before allowing
any definitive recommendation for clinical practice.
Whereas systemic steroids appear to be beneficial in
patients with vasopressor-dependent septic shock and in
patients with early severe acute respiratory distress
syndrome (especially when critical illness-related corti-
costeroid insufficiency is present), their role as adjunctive
treatment in patients with CAP remains controversial
[26-30]. Confalonieri et al. [27] demonstrated that low-
dose glucocorticoid infusion may have beneficial effects
on organ dysfunction in severe pneumonia. Owing to
the small sample size and some baseline imbalances, this
study should be valued as a hypothesis-generating study
rather than as a set of definitive results. In contrast to this
study and other trials suggesting that adjunctive steroid
treatment is advantageous in CAP [28], a recent
randomized, placebo-controlled study could not con-
firm any improved CAP outcome attributed to steroid
treatment [29].
Although adjunctive treatment with glucocorticoids in
severe pneumonia is probably indicated, further rando-
mized clinical trials are urgently needed to confirm the
preliminary positive results and to define optimal dosage
and duration of this treatment. A large (inclusion of
more than 1000 patients is planned) randomized trial
that was initiated by the Veteran Administration
Cooperative Study Group and that will soon be under
way in the US will probably define the significance of
steroid application in CAP treatment.
Prevention
Recent advances in the prevention of CAP include two
dynamic fields: vaccination (i.e., pneumococcal and
influenza vaccination) and the recognition of the
influence of prior medication and conditions (e.g.,
inhaled corticosteroids and smoking).
It has taken many years to successfully develop an
efficacious vaccine against S. pneumoniae. The main
reason is the low immunogenicity of polysaccharides,
which are the target of opsonizing antibodies. Two types
of vaccines are currently in clinical use.
One type of vaccine contains purified capsular poly-
saccharides from 23 of the known 91 pneumococcal
serotypes (pneumococcal polysaccharides vaccine
[PPV]-23). Polysaccharides induce primarily a B cell-
dependent immune response and are not effective in
children younger than 2 years of age (probably due to
their immature immune system). The polysaccharide
vaccine is known to reduce the rate of bacteremia, but
numerous studies and a meta-analysis have demon-
strated little or no effect on the prevention of
pneumococcal pneumonia, particularly in immunose-
nescent or immunosuppressed patients [31]. However,
a recent prospective, multicenter, randomized clinical
trial showed reduction of pneumococcal pneumonia
by 64% in Japanese nursing home residents and
significantly reduced mortality from pneumococcal
pneumonia in patients vaccinated with PPV-23 [32].
In a US cohort study analyzing over 60,000 patients
with HIV, subjects who received PPV-23 had a lower
rate of pneumonia (incidence rate ratio 0.8, 95%
confidence interval 0.8-0.9) than patients who had
never been vaccinated, independently of recent CD4
count, HIV viral load, antiretroviral therapy, and
history of pneumonia [33]. In conclusion, results
regarding the efficacy of PPV-23 in pneumonia remain
controversial.
Pneumococcal conjugate vaccine (PCV) was designed for
children younger than 2 years and initially contained
capsular polysaccharides from seven serotypes. Capsular
polysaccharides of PCV are conjugated to highly
immunogenic proteins, resulting in B- and T-cell
response with consequent mucosal immunity. Studies
have shown that vaccination reduces the carrier rate for
serotypes contained in the vaccine [34]. Since children
are the main reservoir of S. pneumoniae (about 60%
carrier rate), implementation of the conjugated vaccine
has tremendously decreased invasive pneumococcal
diseases by vaccine serotypes not only in vaccinated
but also in non-vaccinated individuals (due to herd
immunity). However, the decrease in disease by vaccine
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of non-vaccine serotypes. This pre-placement of vaccine
serotypes by non-vaccine serotypes is thought to be a
consequence of selective pressure by the PCV-7. Most
data on serotype replacement are from the US, where
PCV-7 was introduced in 2000 [35]. In particular, the
incidence of infections by frequently multiresistant
isolates of serotype 19A, which has now been included
in the extended PCV-13, has risen in the US within the
last few years [36]. However, the role of PCV in
replacement remains an issue of debate since countries
that did not introduce PCV have also observed a rise in
19A and historical surveillance studies from Denmark
report an increase of 19A before the introduction of any
pneumococcal vaccine [37].
The impact of the conjugated vaccine on non-invasive
pneumococcal pneumonia is estimated be much higher.
As for the PPV-23, however, data from randomized
controlled trials are still missing. Currently, the placebo-
controlled Community-Acquired Pneumonia Immuni-
zation Trial in Adults (CAPITA) is investigating the
prevention of a first episode of vaccine serotype-specific
pneumococcal CAP by the conjugated vaccine in 85,000
Dutch community-dwelling adults who are 65 years or
older [38]. The results are pending.
Recently, extended conjugated vaccines with 10 or 13
serotypes have been licensed. Serotype 3 has been
recognized not only as a frequent cause of CAP in adults
but also as an independent risk factor for septic shock
[39]. Therefore, it should be kept in mind that only the
conjugated 13-valent and PPV-23 contain this important
serotype.
Patients with severe chronic obstructive pulmonary
disease (COPD) are at increased risk for exacerbations
and pneumonia. Results on inhaled steroids are con-
flicting. Whereas inhaled steroids decrease the frequency
of exacerbations, a large nested case control study within
a cohort of COPD patients from Quebec (175,906
COPD patients, of whom 23,942 were hospitalized for
pneumonia) demonstrated clearly that inhaled steroids
increase the risk for pneumonia in a dose-dependent
manner [40]. In particular, doses above an equivalent of
fluticasone 1000 mg/day seem to increase the risk
relevantly.
In several epidemiological studies, smoking has been
linked to increased susceptibility to CAP. A recent
investigation uncovered one of the underlying mechan-
isms by demonstrating that smoking suppresses pul-
monary innate host defense by impaired expression of
antimicrobial peptides [41].
Implications for clinical practice
CAP remains a major public health threat. There are
advances in treatment focusing on anti-inflammatory
strategies. Some strategies can easily be transferred to
daily practice (e.g., by using a combination therapy with
macrolides or a respiratory fluoroquinolone with anti-
inflammatory activities instead of beta-lactam mono-
therapy in patients with more severe CAP).
However, currently, the prevention of pneumonia by
vaccination seems to be the most promising field for real
improvement. Since the performance of PPV-23 in this
regard leaves room for improvement, much hope is based
on the extended PCV and the results of the CAPITA study.
In the context of the current aH1N1 pandemic, it
should be kept in mind that the majority of influenza-
associated pneumonia cases are not primary viral
pneumonia but secondary bacterial pneumonias. In
the context of the recent pandemic, several studies
analyzing influenza pandemics of the last century have
been published. S. pneumonia and, to a lesser extent,
Haemophilus influenzae and Staphylococcus aureus were
the leading bacterial causes of secondary pneumonia
[42,43]. In this regard, the impact of combined
influenza and pneumococcal vaccine cannot be
overestimated.
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